GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Gongwin Biopharm Holdings Co 6617.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

108.00

+7.46%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in TWD, from our data supplier.

FY2025

Revenue

TWD 36.4m

FY2016FY2025

Net income

−TWD 114.1m

FY2016FY2025

Free cash flow

−TWD 138.2m

FY2016FY2025

Shareholders' equity

TWD 2.53bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueTWD 36.4mTWD 32.0mTWD 18.9mTWD 1.1mTWD 1.1mTWD 833,000TWD 248,000TWD 62,000TWD 1.1mTWD 93,000
Research and developmentTWD 119.5mTWD 63.3mTWD 52.6mTWD 194.3mTWD 83.1mTWD 76.3mTWD 82.5mTWD 72.1mTWD 83.1mTWD 42.0m
Operating income−TWD 208.9m−TWD 156.1m−TWD 133.3m−TWD 260.7m−TWD 120.8m−TWD 117.4m−TWD 128.8m−TWD 123.8m−TWD 138.1m−TWD 106.9m
Net income−TWD 114.1m−TWD 82.5m−TWD 92.0m−TWD 254.2m−TWD 121.6m−TWD 93.1m−TWD 109.8m−TWD 110.7m−TWD 123.8m−TWD 101.9m
Diluted earnings per share-0.93-0.65-0.81-2.25-1.09-0.88-1.02-1.05-1.21-1.02

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsTWD 2.80bnTWD 3.38bnTWD 1.52bnTWD 1.62bnTWD 1.17bnTWD 1.20bnTWD 774.7mTWD 933.6mTWD 653.9mTWD 790.2m
Cash and short-term investments—————TWD 1.05bnTWD 646.1mTWD 752.9mTWD 532.5mTWD 667.2m
Total liabilitiesTWD 279.2mTWD 281.8mTWD 203.5mTWD 248.7mTWD 184.4mTWD 111.0mTWD 109.1mTWD 162.6mTWD 105.8mTWD 107.8m
Debt—TWD 126.7mTWD 77.2mTWD 141.7mTWD 115.1mTWD 36.1mTWD 23.6mTWD 98.7mTWD 37.3mTWD 24.7m
Shareholders' equityTWD 2.53bnTWD 3.11bnTWD 1.32bnTWD 1.39bnTWD 970.7mTWD 1.09bnTWD 665.6mTWD 770.9mTWD 548.0mTWD 682.4m
Shares outstanding123m126m113m113m111m106m107m105m102m99m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−TWD 135.8m−TWD 87.4m−TWD 110.8m−TWD 232.2m−TWD 95.5m−TWD 87.3m−TWD 99.1m−TWD 108.1m−TWD 108.7m−TWD 92.8m
Capital spending−TWD 2.5m−TWD 206.1m−TWD 1.1m−TWD 6.2m−TWD 54,000−TWD 30.1m−TWD 8.3m−TWD 59.5m−TWD 303,000−TWD 13.9m
Free cash flow−TWD 138.2m−TWD 293.5m−TWD 111.9m−TWD 238.4m−TWD 95.6m−TWD 117.4m−TWD 107.5m−TWD 167.6m−TWD 109.0m−TWD 106.7m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueTWD 12.7mTWD 9.5mTWD 7.9mTWD 12.2mTWD 8.7mTWD 7.6mTWD 8.9mTWD 9.2m
Operating income−TWD 64.4m−TWD 52.9m−TWD 68.4m−TWD 57.0m−TWD 44.6m−TWD 38.9m−TWD 53.7m−TWD 37.5m
Net income−TWD 42.3m−TWD 39.6m−TWD 47.5m−TWD 35.0m−TWD 19.8m−TWD 11.7m−TWD 21.8m−TWD 9.8m
Diluted earnings per share-0.35-0.33-0.39-0.29-0.16-0.09-0.17-0.08
Cash from operations−TWD 59.0m−TWD 41.0m−TWD 55.0m−TWD 38.0m−TWD 16.0m−TWD 24.0m−TWD 24.0m−TWD 25.0m
Capital spending−TWD 1.0m—————−TWD 6.0m—
Free cash flow−TWD 60.0m—————−TWD 30.0m—
Total assetsTWD 2.64bnTWD 2.68bnTWD 2.80bnTWD 2.77bnTWD 2.70bnTWD 3.21bnTWD 3.38bnTWD 3.45bn
Shareholders' equityTWD 2.33bnTWD 2.40bnTWD 2.53bnTWD 2.52bnTWD 2.47bnTWD 2.96bnTWD 3.11bnTWD 3.19bn

Financial ratios

Data as of 7 Oct 2026

FY2025FY2024FY2023FY2022FY2021
Operating margin-317.5%-273.3%-496.9%-25279.8%-10571.0%
Net margin-313.1%-257.6%-486.6%-22238.8%-10637.0%
Return on equity-4.5%-2.7%-7.0%-18.3%-12.5%
Return on assets-4.1%-2.4%-6.1%-15.7%-10.4%
Revenue growth13.8%69.4%1554.9%0.0%—
Earnings growth38.3%-10.3%-63.8%109.1%—
Current ratio10.36x13.36x8.86x6.99x5.95x
Equity ratio90.5%91.9%86.8%85.8%82.8%
Interest coverage-22.42x-20.35x-13.07x-90.72x-102.39x
R&D as a share of sales327.8%197.5%278.3%17000.9%7266.3%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue217.1%112.9%—
Operating income-7.1%12.2%15.3%
Net income-23.4%4.2%9.2%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-533.1%-857.3%-1101.7%—
Net margin-287.2%-613.1%-836.9%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Price to earnings-92.5-173.3-221.0-138.6-253.6-270.9-75.4-61.1-51.3
Price to sales289.7446.6———————

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.